218 related articles for article (PubMed ID: 17568025)
1. Erythropoietin, the FDA, and oncology.
Steinbrook R
N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025
[No Abstract] [Full Text] [Related]
2. Rebates for anti-anemia drugs draw response from FDA, CMS.
Sipkoff M
Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
[No Abstract] [Full Text] [Related]
3. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
Steensma DP
J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
[No Abstract] [Full Text] [Related]
4. Managing anemia: what do we do now?
Neumann ME
Nephrol News Issues; 2007 May; 21(6):50, 52. PubMed ID: 17518123
[No Abstract] [Full Text] [Related]
5. Weighing the hazards of erythropoiesis stimulation in patients with cancer.
Khuri FR
N Engl J Med; 2007 Jun; 356(24):2445-8. PubMed ID: 17568023
[No Abstract] [Full Text] [Related]
6. Biosimilar epoetins.
Macdougall IC
Nephrol Dial Transplant; 2009 May; 24(5):1698-9; author reply 1699-700. PubMed ID: 19366858
[No Abstract] [Full Text] [Related]
7. Erythropoietin: high profile, high scrutiny.
Crawford J
J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
[No Abstract] [Full Text] [Related]
8. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
Winkelmayer WC
J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031
[No Abstract] [Full Text] [Related]
9. FDA panel scrutinizes safety of anti-anemia drugs.
Randal J
J Natl Cancer Inst; 2004 Jul; 96(14):1061. PubMed ID: 15265966
[No Abstract] [Full Text] [Related]
10. New oversight put in place for physicians giving anemia drugs to patients with cancer.
Mitka M
JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885
[No Abstract] [Full Text] [Related]
11. The FDA, stocks, black boxes and ESAs.
Spry L
Nephrol News Issues; 2007 May; 21(6):53-4. PubMed ID: 17518124
[No Abstract] [Full Text] [Related]
12. New limits advised for anemia drugs.
Mitka M
JAMA; 2007 Jun; 297(22):2464. PubMed ID: 17565074
[No Abstract] [Full Text] [Related]
13. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
[TBL] [Abstract][Full Text] [Related]
14. FDA notifications. FDA issues public health advisory about ESAs.
AIDS Alert; 2007 May; 22(5):57-8. PubMed ID: 17580370
[No Abstract] [Full Text] [Related]
15. [Recent advances on the use of erythropoietin in oncology].
Spaƫth D
Bull Cancer; 2006 May; 93(5):489-93. PubMed ID: 16777627
[TBL] [Abstract][Full Text] [Related]
16. FDA finalizes REMS program for ESAs; Amgen continues to study risks.
Brower V
J Natl Cancer Inst; 2010 May; 102(9):592-3. PubMed ID: 20421565
[No Abstract] [Full Text] [Related]
17. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
Yang MC
Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
[No Abstract] [Full Text] [Related]
18. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia.
Lappin TR; Maxwell AP; Johnston PG
Oncologist; 2007 Apr; 12(4):362-5. PubMed ID: 17470677
[No Abstract] [Full Text] [Related]
19. ESAs further restricted, but debate continues.
Brower V
J Natl Cancer Inst; 2008 Oct; 100(19):1344-51. PubMed ID: 18812542
[No Abstract] [Full Text] [Related]
20. Safety concerns for two big anemia drugs.
Nursing; 2008 Oct; 38(10):12. PubMed ID: 18812980
[No Abstract] [Full Text] [Related]
[Next] [New Search]